cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30919070.v1
title: Impact of repetitive transcranial magnetic stimulation combined with traditional Chinese Tuina for stroke: a systematic review and meta-analysis

description: Stroke has emerged as one of the leading causes of long-term disability worldwide. Although the therapeutic effects of traditional Chinese Tuina and rTMS as monotherapies have been partially established, research on their combined application in stroke rehabilitation remains limited. This meta-analysis aims to investigate the effects of traditional Chinese Tuina combined with rTMS for stroke. Nine databases, including EMBASE, PubMed, Cochrane Central Register of Controlled Trials, Web of Science, Alternative HealthWatch, VIP, Wanfang, CNKI and the Chinese Biomedical Literature Database, were searched from inception to August 5, 2025. Two authors independently performed literature screening, data extraction, and risk-of-bias assessment. Meta-analysis was conducted using STATA software. Eleven studies involving 1,134 patients were included in this meta-analysis. The meta-analysis indicated that, compared to the control group, the intervention group demonstrated significantly higher motor function scores [<i>p</i> &lt; 0.001] and life quality [<i>p</i> &lt; 0.001]. The intervention group also exhibited lower depression scores [<i>p</i> &lt; 0.001] and sleep scores [<i>p</i> &lt; 0.001]. The meta-regression analysis results showed that coil type had a significant impact on quality of life [<i>p &lt;</i> 0.001]; session count and stimulation frequency independently had a marginally significant impact on motor function [<i>p</i> = 0.09 &lt; 0.1]; and quality of life [<i>p</i> = 0.06 &lt; 0.1]. Subgroup analysis suggested that 24 rTMS sessions may yield the most favourable improvement in motor function for post-stroke patients [<i>p</i> &lt; 0.001], while low-frequency and 8-coil demonstrate optimal efficacy in enhancing patients’ quality of life [<i>p</i> &lt; 0.001; <i>p</i> &lt; 0.001]. No publication bias was detected across the analyses. The combination of rTMS and Tuina significantly improves motor function, enhances quality of life, alleviates depressive symptoms, and improves sleep quality for stroke. 24 rTMS sessions may yield the most favourable improvement in motor function. Moreover, low-frequency and 8-coil demonstrate optimal efficacy in enhancing patients’ quality of life.
DOI: 10.6084/m9.figshare.29424256
title: Incidence and risk factors for recurrent membranous nephropathy after kidney transplantation: a systematic review and meta-analysis

description: The risk factors for membranous nephropathy (MN) following kidney transplantation remain unclear, mainly attributed to the constrained identification of predictive clinical presentation features. This study aims to conduct a systematic review to analyse the risk factors associated with recurrent MN. Starting from its establishment until March 2023, we conducted a screening of case–control studies focusing on recurrent MN in various databases including PubMed, Embase, Web of Science, Medline, the Cochrane Library, CNKI, Wanfang, CBMdisc and Weipu. The protocol was registered on PROSPERO (CRD42022315448). A meta-analysis was carried out to examine the risk factors for recurrent MN, and statistical analysis was performed using Stata 12.0. This meta-analysis included a total of eight case–control studies with 108 patients with recurrent MN and 298 without recurrence. The results showed the incidence of recurrent MN after kidney transplantation was 34%. A higher rate of recurrent MN detected through surveillance biopsies was observed compared to indication biopsies. Living donor [OR = 1.89, 95%CI (1.12, 3.19), and <i>p</i> = 0.017], anti-phospholipase A2 receptor autoantibody (anti-PLA2R) levels before transplantation [OR = 10.16, 95%CI (3.16, 32.62), and <i>p</i> &lt; 0.001] and a shorter duration of dialysis [weighted mean difference (WMD) = −14.36 mo, 95%CI (-24.60, −4.13), and <i>p</i> = 0.006] were associated with a risk for recurrent MN; induction immunosuppression [OR = 0.24, 95%CI (0.10, 0.58), and <i>p</i> = 0.001] and tacrolimus use [OR = 0.23, 95%CI (0.09, 0.61), and <i>p</i> = 0.003] were protective factors for recurrent primary MN, whereas sex, age, time from MN to end-stage renal disease (ESRD), re-transplantation, and race (white) were not associated with recurrent MN. Recurrence of MN persists with a high rate. These factors should be carefully evaluated in clinical decision-making, encompassing living donor selection, pre-transplant anti-PLA2R levels, dialysis, choice of induction immunosuppression, and tacrolimus use.
DOI: 10.6084/m9.figshare.29424256.v1
title: Incidence and risk factors for recurrent membranous nephropathy after kidney transplantation: a systematic review and meta-analysis

description: The risk factors for membranous nephropathy (MN) following kidney transplantation remain unclear, mainly attributed to the constrained identification of predictive clinical presentation features. This study aims to conduct a systematic review to analyse the risk factors associated with recurrent MN. Starting from its establishment until March 2023, we conducted a screening of case–control studies focusing on recurrent MN in various databases including PubMed, Embase, Web of Science, Medline, the Cochrane Library, CNKI, Wanfang, CBMdisc and Weipu. The protocol was registered on PROSPERO (CRD42022315448). A meta-analysis was carried out to examine the risk factors for recurrent MN, and statistical analysis was performed using Stata 12.0. This meta-analysis included a total of eight case–control studies with 108 patients with recurrent MN and 298 without recurrence. The results showed the incidence of recurrent MN after kidney transplantation was 34%. A higher rate of recurrent MN detected through surveillance biopsies was observed compared to indication biopsies. Living donor [OR = 1.89, 95%CI (1.12, 3.19), and <i>p</i> = 0.017], anti-phospholipase A2 receptor autoantibody (anti-PLA2R) levels before transplantation [OR = 10.16, 95%CI (3.16, 32.62), and <i>p</i> &lt; 0.001] and a shorter duration of dialysis [weighted mean difference (WMD) = −14.36 mo, 95%CI (-24.60, −4.13), and <i>p</i> = 0.006] were associated with a risk for recurrent MN; induction immunosuppression [OR = 0.24, 95%CI (0.10, 0.58), and <i>p</i> = 0.001] and tacrolimus use [OR = 0.23, 95%CI (0.09, 0.61), and <i>p</i> = 0.003] were protective factors for recurrent primary MN, whereas sex, age, time from MN to end-stage renal disease (ESRD), re-transplantation, and race (white) were not associated with recurrent MN. Recurrence of MN persists with a high rate. These factors should be carefully evaluated in clinical decision-making, encompassing living donor selection, pre-transplant anti-PLA2R levels, dialysis, choice of induction immunosuppression, and tacrolimus use.
DOI: 10.6084/m9.figshare.28284600.v1
title: The methyl-CpG binding domain 2 regulates peptidylarginine deiminase 4 expression and promotes neutrophil extracellular trap formation via the Janus kinase 2 signaling pathway in experimental severe asthma

description: The prognosis for severe asthma is poor, and the current treatment options are limited. The methyl-CpG binding domain protein 2 (MBD2) participates in neutrophil-mediated severe asthma through epigenetic regulation. Neutrophil extracellular traps (NETs) play a critical role in the pathogenesis of severe asthma. This study aims to detect if MBD2 can reduce NETs formation and the potential mechanism in severe asthma. A severe asthma model was established in C57BL/6 wild-type mice exposure to house dust mite (HDM), ovalbumin (OVA), and lipopolysaccharide (LPS). Enzyme-linked immunosorbent assay was used to measure the concentrations of IL-4, IL-17A, and IFN-γ in lung tissues. Flow cytometry was employed to determine the percentages of Th2, Th17, and Treg cells in lung tissues. Quantitative real-time polymerase chain reaction was utilized to assess the mRNA expression levels of MBD2, JAK2, and PAD4. Western blotting and immunofluorescence were conducted to detect the protein of MBD2, JAK2, PAD4, and CitH3. HL-60 cells were differentiated into neutrophil-like cells by culturing in a medium containing dimethyl sulfoxide and then stimulated with LPS. KCC-07, Ruxolitinib, and Cl-amidine were used to inhibit the expressions of MBD2, JAK2, and PAD4, respectively. Severe asthma mice were characterized by pulmonary neutrophilic inflammation and increased formation of neutrophil extracellular traps (NETs). The expression of MBD2, JAK2, and PAD4 was elevated in severe asthma mice. Inhibiting the expression of MBD2, JAK2, and PAD4 reduced NETs formation and decreased airway inflammation scores, total cell counts and neutrophil counts in BALF, and percentage of Th2 and Th17 cell in lung tissues, whereas increasing Treg cell counts. In both severe asthma mice and HL-60-differentiated neutrophil-like cells <i>in vitro</i>, inhibiting MBD2 reduced the mRNA and protein expression of JAK2 and PAD4, and inhibiting JAK2 reduced the expression of PAD4 mRNA and protein. MBD2 regulates PAD4 expression through the JAK2 signaling pathway to promote NETs formation in mice with severe asthma. Further bench-based and bedside-based studies targeting the MBD2, PAD4, and JAK2 signaling pathways will help open new avenues for drug development of severe asthma.
DOI: 10.6084/m9.figshare.30646124
title: Exercise-induced modulation of IGF-1 in healthy, obese, and cancer populations: a systematic review and meta-analysis

description: This systematic review and meta-analysis evaluated the effects of chronic exercise on circulating insulin-like growth factor 1 (IGF-1) across different populations, including, healthy adults, individuals with obesity, and cancer patients or survivors. To minimize confounding, we excluded trials combining exercise with medications, hormone therapy, or structured dietary interventions. PubMed and Embase were searched through July 2024 for randomized controlled trials (RCTs) in adults (≥18 years) with exercise interventions lasting ≥8 weeks, a non-exercise control group, and reported changes in serum IGF-1. Twenty-one RCTs with 1376 participants met the inclusion criteria. Pooled weighted mean differences (WMD) with 95% confidence intervals (CI) were calculated, and trial sequential analysis was used to assess robustness. Exercise significantly increased IGF-1 in healthy individuals (WMD=21.41, 95% CI 8.01–34.81) and in those with obesity (WMD=15.46, 95% CI -1.07–31.99), consistent with metabolic and anabolic benefits via the GH–IGF-1 axis. In contrast, exercise significantly reduced IGF-1 in cancer patients or survivors (WMD=-14.71, 95% CI -19.77 to -9.65). In studies reporting both IGF-1 and IGF-binding protein 3 (IGFBP-3), exercise increased IGFBP-3 in healthy and cancer populations, suggesting a modulatory role of IGFBP-3 in IGF-1 regulation, particularly in cancer. Chronic exercise exerts health status–dependent effects on circulating IGF-1, supporting metabolic benefits in healthy and obese individuals and potentially contributing to cancer care by reducing IGF-1 in cancer patients or survivors. These findings demonstrate the complex endocrine response to exercise and support the therapeutic potential of tailored exercise prescriptions. .
DOI: 10.6084/m9.figshare.30646124.v1
title: Exercise-induced modulation of IGF-1 in healthy, obese, and cancer populations: a systematic review and meta-analysis

description: This systematic review and meta-analysis evaluated the effects of chronic exercise on circulating insulin-like growth factor 1 (IGF-1) across different populations, including, healthy adults, individuals with obesity, and cancer patients or survivors. To minimize confounding, we excluded trials combining exercise with medications, hormone therapy, or structured dietary interventions. PubMed and Embase were searched through July 2024 for randomized controlled trials (RCTs) in adults (≥18 years) with exercise interventions lasting ≥8 weeks, a non-exercise control group, and reported changes in serum IGF-1. Twenty-one RCTs with 1376 participants met the inclusion criteria. Pooled weighted mean differences (WMD) with 95% confidence intervals (CI) were calculated, and trial sequential analysis was used to assess robustness. Exercise significantly increased IGF-1 in healthy individuals (WMD=21.41, 95% CI 8.01–34.81) and in those with obesity (WMD=15.46, 95% CI -1.07–31.99), consistent with metabolic and anabolic benefits via the GH–IGF-1 axis. In contrast, exercise significantly reduced IGF-1 in cancer patients or survivors (WMD=-14.71, 95% CI -19.77 to -9.65). In studies reporting both IGF-1 and IGF-binding protein 3 (IGFBP-3), exercise increased IGFBP-3 in healthy and cancer populations, suggesting a modulatory role of IGFBP-3 in IGF-1 regulation, particularly in cancer. Chronic exercise exerts health status–dependent effects on circulating IGF-1, supporting metabolic benefits in healthy and obese individuals and potentially contributing to cancer care by reducing IGF-1 in cancer patients or survivors. These findings demonstrate the complex endocrine response to exercise and support the therapeutic potential of tailored exercise prescriptions. .
DOI: 10.6084/m9.figshare.28253978
title: Trends of cause-specific cardiovascular disease mortality in China, 2009-2019: a nationwide longitudinal study

description: Cardiovascular disease (CVD) is the top cause of death in China. We aimed to identify trends in cause-specific CVD mortality in a rapidly developing country, thereby providing evidence for CVD prophylaxis. Using raw data from the Chinese National Mortality Surveillance (CNMS) system, we assessed the mortalities of all CVD and cause-specific CVD during 2009-2019. Temporal trends of crude mortality rates (CMRs) and age-standardized mortality (ASMRs) of CVD were evaluated using joinpoint regression models. Age-sex-specific CVD mortality rates were predicted by using age-period-cohort Poisson regression model. A total of 10,608,402 CVD death occurred during 2009-2019, accounting for 49.8% of all-cause of death in China. The three major CVD types [cerebrovascular disease, ischemic heart disease (IHD) and hypertensive disease (HD)] accounted for 94.6% of total CVD deaths. The CMR of all CVD increased [the annual average percentage change (AAPC) = 3.4%, 95% confidence interval (CI) 2.6% to 4.1%] while the ASMR decreased (AAPC = −2.0%, 95% CI −3.5% to −0.6%). Cerebrovascular disease is predicted to be the leading cause of CVD death in men and IHD will be the top cause of CVD death in women over the period 2025-2029. Although the ASMR of total CVD decreased, CVD remained the leading cause of death in China. Cerebrovascular disease, IHD and HD were the major three leading causes of CVD-related death. Inflammatory heart disease-associated death increased in the young population. Attention should be paid to premature deaths associated with cerebrovascular disease and rheumatic heart disease among rural residents.
DOI: 10.6084/m9.figshare.28284600
title: The methyl-CpG binding domain 2 regulates peptidylarginine deiminase 4 expression and promotes neutrophil extracellular trap formation via the Janus kinase 2 signaling pathway in experimental severe asthma

description: The prognosis for severe asthma is poor, and the current treatment options are limited. The methyl-CpG binding domain protein 2 (MBD2) participates in neutrophil-mediated severe asthma through epigenetic regulation. Neutrophil extracellular traps (NETs) play a critical role in the pathogenesis of severe asthma. This study aims to detect if MBD2 can reduce NETs formation and the potential mechanism in severe asthma. A severe asthma model was established in C57BL/6 wild-type mice exposure to house dust mite (HDM), ovalbumin (OVA), and lipopolysaccharide (LPS). Enzyme-linked immunosorbent assay was used to measure the concentrations of IL-4, IL-17A, and IFN-γ in lung tissues. Flow cytometry was employed to determine the percentages of Th2, Th17, and Treg cells in lung tissues. Quantitative real-time polymerase chain reaction was utilized to assess the mRNA expression levels of MBD2, JAK2, and PAD4. Western blotting and immunofluorescence were conducted to detect the protein of MBD2, JAK2, PAD4, and CitH3. HL-60 cells were differentiated into neutrophil-like cells by culturing in a medium containing dimethyl sulfoxide and then stimulated with LPS. KCC-07, Ruxolitinib, and Cl-amidine were used to inhibit the expressions of MBD2, JAK2, and PAD4, respectively. Severe asthma mice were characterized by pulmonary neutrophilic inflammation and increased formation of neutrophil extracellular traps (NETs). The expression of MBD2, JAK2, and PAD4 was elevated in severe asthma mice. Inhibiting the expression of MBD2, JAK2, and PAD4 reduced NETs formation and decreased airway inflammation scores, total cell counts and neutrophil counts in BALF, and percentage of Th2 and Th17 cell in lung tissues, whereas increasing Treg cell counts. In both severe asthma mice and HL-60-differentiated neutrophil-like cells <i>in vitro</i>, inhibiting MBD2 reduced the mRNA and protein expression of JAK2 and PAD4, and inhibiting JAK2 reduced the expression of PAD4 mRNA and protein. MBD2 regulates PAD4 expression through the JAK2 signaling pathway to promote NETs formation in mice with severe asthma. Further bench-based and bedside-based studies targeting the MBD2, PAD4, and JAK2 signaling pathways will help open new avenues for drug development of severe asthma.
DOI: 10.6084/m9.figshare.30383385
title: Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study

description: The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is increasing. While daily aspirin use has been associated with reduced hepatocellular carcinoma (HCC) risk in NAFLD, its impact on mortality and liver-related outcomes in MASLD remains unclear. This retrospective, multi-institutional cohort study included 48,722 MASLD patients from 2008 to 2020, divided into aspirin users and non-users. Exclusion criteria included significant cardiac disease unrelated to aspirin, alcoholic liver disease, incomplete follow-up, and concomitant use of other antiplatelet therapies. Propensity score matching (PSM) was performed to balance baseline characteristics, including demographics, cirrhosis status, ALT levels, cardiovascular conditions, and concurrent medications. After PSM, 2003 patients were included in each cohort. Aspirin users had a mean duration of use of 4.59 ± 3.97 years, with 97% on a daily dose of 75–100 mg. Over three years, aspirin use was not significantly associated with reductions in overall mortality, liver-related events, liver-related mortality, or HCC incidence compared to non-users. However, a trend toward lower liver-related mortality and HCC incidence was observed without an increased risk of major bleeding. In this large cohort, daily aspirin use alone did not significantly reduce mortality or liver-related events in MASLD patients over three years. The observed trends may suggest potential long-term benefits, warranting further investigation into extended aspirin duration and combination strategies for MASLD management.
DOI: 10.6084/m9.figshare.30383385.v1
title: Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study

description: The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is increasing. While daily aspirin use has been associated with reduced hepatocellular carcinoma (HCC) risk in NAFLD, its impact on mortality and liver-related outcomes in MASLD remains unclear. This retrospective, multi-institutional cohort study included 48,722 MASLD patients from 2008 to 2020, divided into aspirin users and non-users. Exclusion criteria included significant cardiac disease unrelated to aspirin, alcoholic liver disease, incomplete follow-up, and concomitant use of other antiplatelet therapies. Propensity score matching (PSM) was performed to balance baseline characteristics, including demographics, cirrhosis status, ALT levels, cardiovascular conditions, and concurrent medications. After PSM, 2003 patients were included in each cohort. Aspirin users had a mean duration of use of 4.59 ± 3.97 years, with 97% on a daily dose of 75–100 mg. Over three years, aspirin use was not significantly associated with reductions in overall mortality, liver-related events, liver-related mortality, or HCC incidence compared to non-users. However, a trend toward lower liver-related mortality and HCC incidence was observed without an increased risk of major bleeding. In this large cohort, daily aspirin use alone did not significantly reduce mortality or liver-related events in MASLD patients over three years. The observed trends may suggest potential long-term benefits, warranting further investigation into extended aspirin duration and combination strategies for MASLD management.
DOI: 10.6084/m9.figshare.28253978.v1
title: Trends of cause-specific cardiovascular disease mortality in China, 2009-2019: a nationwide longitudinal study

description: Cardiovascular disease (CVD) is the top cause of death in China. We aimed to identify trends in cause-specific CVD mortality in a rapidly developing country, thereby providing evidence for CVD prophylaxis. Using raw data from the Chinese National Mortality Surveillance (CNMS) system, we assessed the mortalities of all CVD and cause-specific CVD during 2009-2019. Temporal trends of crude mortality rates (CMRs) and age-standardized mortality (ASMRs) of CVD were evaluated using joinpoint regression models. Age-sex-specific CVD mortality rates were predicted by using age-period-cohort Poisson regression model. A total of 10,608,402 CVD death occurred during 2009-2019, accounting for 49.8% of all-cause of death in China. The three major CVD types [cerebrovascular disease, ischemic heart disease (IHD) and hypertensive disease (HD)] accounted for 94.6% of total CVD deaths. The CMR of all CVD increased [the annual average percentage change (AAPC) = 3.4%, 95% confidence interval (CI) 2.6% to 4.1%] while the ASMR decreased (AAPC = −2.0%, 95% CI −3.5% to −0.6%). Cerebrovascular disease is predicted to be the leading cause of CVD death in men and IHD will be the top cause of CVD death in women over the period 2025-2029. Although the ASMR of total CVD decreased, CVD remained the leading cause of death in China. Cerebrovascular disease, IHD and HD were the major three leading causes of CVD-related death. Inflammatory heart disease-associated death increased in the young population. Attention should be paid to premature deaths associated with cerebrovascular disease and rheumatic heart disease among rural residents.